SEARCH

Contact Information

thomas.beimers​@FaegreBD.com

2200 Wells Fargo Center
90 S. Seventh Street

Minneapolis, Minnesota 55402

T: +1 612 766 8856
F: +1 612 766 1600

Education

University of Minnesota Law School
J.D., magna cum laude, Minnesota Law Review (articles editor) (1998)
Macalester College
B.A. in Political Science (1991)

Bar Admissions

District of Columbia Minnesota

Court Admissions

U.S. Court of Appeals for the District of Columbia Circuit U.S. Court of Appeals for the Eighth Circuit U.S. Court of Appeals for the Fifth Circuit U.S. Court of Appeals for the Fourth Circuit U.S. Supreme Court U.S. Court of Appeals for the Ninth Circuit

Thomas W. Beimers

Partner

Tom Beimers represents a wide range of health care and life science industry clients in False Claims Act cases, government investigations, and other criminal, civil and administrative proceedings. Tom’s practice includes the following types of engagements:

Health Care Fraud and Abuse

  • Represent medical device and pharmaceutical manufacturers, distributors, health care systems, laboratories and DME suppliers in False Claims Act investigations throughout the United States
  • Respond to criminal, civil and administrative subpoenas from U.S. Department of Justice (DOJ), Inspector General offices and state agencies
  • Investigate Anti-Kickback Statute, Stark Law and Exclusion Statute matters

White Collar and Investigations

  • Defense of entities and individuals in white collar criminal matters
  • Government and internal investigations, including False Claims Act, Foreign Corrupt Practices Act (FCPA), Civil Monetary Penalties Law, Food and Drug Administration (FDA), Federal Trade Commission (FTC), State Attorneys General, Medicaid Fraud Control Units and notified body inquiries
  • Subpoena response

Compliance and Risk Management

  • Served as interim compliance officer for major medical device manufacturer
  • Compliance assessments and internal investigations
  • Advise clients on FCPA, Sunshine Act, Health Insurance Portability and Accountability Act (HIPAA), Corporate Integrity Agreements, drug price reporting and other regulatory compliance issues

Litigation

  • Complex litigation, including FCA, FCPA, RICO, securities fraud, pharmaceutical pricing, constitutional law, and Medicare and Medicaid reimbursement

Before joining Faegre Baker Daniels, Tom was senior counsel for administrative and civil remedies in the Department of Health and Human Services' Office of the Inspector General. At OIG, he investigated False Claims Act cases involving off-label marketing, drug pricing, Anti-Kickback Statute violations, and Medicaid and Medicare reimbursement. From 2008 to 2010, Tom served as Special Assistant U.S. Attorney in Detroit, prosecuting criminal health care fraud cases as part of the joint HHS-DOJ Medicare Fraud Strike Force.

Tom is a frequent national speaker and author on topics related to health care fraud and abuse, white collar criminal defense, and compliance matters.

Honors

  • HHS Inspector General's Exceptional Achievement Award, 2010-11
  • Department of Justice Assistant Attorney General's Award, 2010
  • FBI Commendation in recognition of exceptional prosecutorial skills, 2010
  • Minnesota Law Review — Outstanding Student Comment, 1998
  • Robert A. Stein Scholar, 1995-98

Professional Associations

  • American Health Lawyers Association
  • Health Care Compliance Association
  • Federal Bar Association
  • American Bar Association
  • Warren E. Burger Inn of Court

Civic Activities

  • Jungle Theater, Minneapolis — Board of Directors
  • Harvard World Teach Program — Former Volunteer English Teacher

Clerkships

  • Eighth Circuit Court of Appeals, Hon. Gerald W. Heaney, 1998-99

Presentations

  • Strategies for Avoiding and Responding to Health Care Fraud and Abuse Claims
    Moderator and panelist, ALI CLE Webinar, May 6, 2015
  • Lessons From the Latest in Fraud and Abuse Enforcement
    Moderator, Minnesota State Bar Association Health Law Institute, June 2014
  • Navigating the DME Jungle
    Health Care Compliance Association Compliance Institute, San Diego, April 2014
  • Investigations for Life Sciences Companies: What to Do When the Government Knocks
    Indianapolis Bar Association CLE Update, February 2014
  • The Best Defense: Revamping Compliance Programs Based on Takeaways From Recent Corporate Integrity Agreements
    Fraud and Abuse in the Sales and Marketing of Drugs Conference, New York, March 2013
  • The Sunshine Act Final Rule
    LifeScience Alley, Minneapolis, March 2013
  • Agency Expectations for Compliance Programs
    13th Annual Pharmaceutical Regulatory and Compliance Congress, Washington, D.C., November 2012
  • How New Corporate Integrity Agreements Impact Physician Practices
    Health Care Compliance Association Clinical Practice Compliance Conference, Philadelphia, October 2012
  • New Standards: What Enhanced Corporate Integrity Obligations Tell Us About OIG Expectations for Compliance Programs
    AHLA/HCCA Fraud and Compliance Forum, Baltimore, September 2012
  • What Is the OIG Telling Us About Current Expectations for Compliance Programs?
    Health Care Compliance Association Compliance Institute, Las Vegas, May 2012
  • Importance of Timely Average Manufacturer's Price Reporting
    Healthcare Distribution Management Association, Washington, D.C., November 2010

Published Articles

  • CMS Holds Webinar Explaining Open Payments Phase I
    Beyond Healthcare Reform, February 28, 2014
  • CMS and OIG Announce Plan to Exclude “Recalcitrant Providers”
    Beyond Healthcare Reform, January 31, 2014
  • Invoking the Anti-Kickback Statute Can Backfire
    Beyond Healthcare Reform, November 18, 2013
  • Is Off-Label Enforcement Off Limits?
    Beyond Healthcare Reform, December 7, 2012
  • With Boehringer Ingelheim FCA Settlement, Government Continues to Expand Off-Label Enforcement and Expand CIAs
    Beyond Healthcare Reform, October 31, 2012
  • Caught by the CIA: Corporate Integrity Agreement Is Grounds for FCA Liability
    AHLA Fraud & Abuse Newsletter, June 2012
  • The Departmental Appeals Board (Re)Defines the "Should Have Known" Standard for Exclusion Actions Under 1128(b)(7)
    Beyond Healthcare Reform, April 19, 2012
  • OIG Reports on Pharma Compliance Roundtable
    Beyond Healthcare Reform, March 28, 2012
  • District Court Decisions Help Refine Heightened Pleading Standard for False Claims Act Cases
    Beyond Healthcare Reform, March 15, 2012
  • Where Is the Corporate Integrity Agreement?
    Law360, February 27, 2012
  • Searching for the Structural Vision of City of Boerne v. Flores: Vertical and Horizontal Tensions in the New Constitutional Architecture
    26 Hastings Const. L.Q. 789, 1999

DISCLAIMER

Transmission of information to us via this feature does not establish an attorney-client relationship. Do not send any information that you would have treated confidentially.